Statin Use Key to Reducing CV Risk in Rheumatoid Arthritis Patients on Tofacitinib: ORAL Surveillance Analysis Medha Baranwal22 Nov 2024 2:00 AM ISTUSA: A recent post hoc analysis of the ORAL Surveillance trial has highlighted the essential role of statins in mitigating major adverse...
Twice-Daily Deuruxolitinib Significantly Improves Alopecia Areata Over 24 Weeks: Study Dr Riya Dave11 Oct 2024 8:00 PM ISTResearchers found that twice-daily deuruxolitinib (Leqselvi), at an 8 mg dose, significantly improved hair satisfaction of patients with severe...
JAK Inhibitors Linked to Lower AMD Risk in Autoimmune Patients, suggests JAMA study Dr Riya Dave16 July 2024 6:15 AM ISTResearch has shown that the rate of Age-related macular degeneration (AMD) in patients with autoimmune disorders treated with Janus kinase (JAK)...
All JAK inhibitors found effective for treatment of rheumatoid arthritis in real life setting Dr. Kamal Kant Kohli12 Jan 2024 6:15 AM ISTAccording to a new paper in Rheumatology, published by Oxford University Press, JAK inhibitors, which doctors have used to treat patients with...
Medical Bulletin 10/November/2023 Isra Zaman10 Nov 2023 3:15 PM ISTHere are the top medical news of the day:Do allergic conditions increase the risk of developing Long-COVID after SARS-CoV-2 infection?In an analysis...
Study finds JAK inhibitors and tocilizumab effective in VEXAS syndrome Isra Zaman10 Nov 2023 9:30 AM ISTA recent study presented at ACR Convergence 2023 has offered newfound hope for individuals battling VEXAS syndrome, a rare and often lethal autoimmune...
Medical Bulletin 03/November/2023 Isra Zaman3 Nov 2023 3:15 PM ISTHere are the top medical news of the day:JAK inhibitors show promising efficacy in rheumatoid arthritis treatmentA retrospective multicenter study...
JAK inhibitors show promising efficacy in rheumatoid arthritis treatment Isra Zaman3 Nov 2023 9:30 AM ISTA retrospective multicenter study conducted by Japanese researchers has found that Janus kinase (JAK) inhibitors, a class of drugs used to treat...
FDA approves JAK inhibitor Momelotinib for Myelofibrosis in Anemic adults Isra Zaman19 Sept 2023 9:30 AM ISTThe US Food and Drug Administration (FDA) has approved momelotinib for the treatment of intermediate or high-risk myelofibrosis, including primary...
Treatment with JAK inhibitor for myelofibrosis leads to Mycobacterium marinum skin infection: A case report Medha Baranwal14 July 2023 9:15 AM ISTChina: A recent article published in Clinical, Cosmetic and Investigational Dermatology reports the case of mycobacterium marinum skin infection in...
JAK inhibitors feasible treatment option for patients with Pyoderma gangrenosum Medha Baranwal1 Jun 2023 2:30 AM ISTBrazil: A recent study has stated that JAK inhibitors could be a potential alternative for treating pyoderma gangrenosum (PG) in certain patients,...
JAK inhibitors use in immune-mediated inflammatory diseases not tied to thromboembolic risk Aditi31 May 2023 8:45 AM ISTAn article published in Rheumatology has concluded that JAK inhibitors are not tied to an increased risk of thromboembolic than placebo in...
